News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Aurobindo has one of the most enduring generics ecosystems among peers
The company plans to enter the EU markets in FY22
The company is working closely with its six manufacturing partners in India
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
Subscribe To Our Newsletter & Stay Updated
